Clinical Trial

Immune Modulation by Exosomes in COVID-19

Study acronym: IMECOV19
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 17, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-01-12; most recent amendment 2024-01-16.
Trial Details
NCT Number NCT05191381
Lead Sponsor University of Ulm
Conditions COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis
Enrollment 40 participants
Start Date 2021-12-22
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-17